HTX-011 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Analgesia
Conditions
Analgesia
Trial Timeline
Jun 1, 2015 → Sep 1, 2015
NCT ID
NCT02471898About HTX-011 + Placebo
HTX-011 + Placebo is a phase 2 stage product being developed by Heron Therapeutics for Analgesia. The current trial status is completed. This product is registered under clinical trial identifier NCT02471898. Target conditions include Analgesia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02471898 | Phase 2 | Completed |
Competing Products
20 competing products in Analgesia
Other Products from Heron Therapeutics
SUSTOLApproved
77
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenApproved
77
Bupivacaine HClApproved
77
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenApproved
77
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionApproved
77